Reported outcomes in transsphenoidal surgery for pituitary adenomas: a systematic review

被引:5
|
作者
Layard Horsfall, Hugo [1 ,2 ,3 ,4 ]
Lawrence, Alistair [5 ]
Venkatesh, Ashwin
Loh, Ryan T. S.
Jayapalan, Ronie [1 ,2 ]
Koulouri, Olympia [6 ,7 ,8 ,9 ]
Sharma, Rishi [2 ,10 ]
Santarius, Thomas [1 ,2 ]
Gurnell, Mark [6 ,7 ,8 ,9 ]
Dorward, Neil [3 ]
Mannion, Richard [1 ,2 ]
Marcus, Hani J. [3 ,4 ]
Kolias, Angelos G. [1 ,2 ]
机构
[1] Addenbrookes Hosp, Dept Clin Neurosci, Div Neurosurg, Cambridge, England
[2] Univ Cambridge, Cambridge, England
[3] Natl Hosp Neurol & Neurosurg, Dept Neurosurg, Queen Sq, London W1CN 3BG, England
[4] UCL, Wellcome EPSRC Ctr Intervent & Surg Sci, London, England
[5] Royal London Hosp, Dept Neurosurg, London, England
[6] Univ Cambridge, Clin Sch Med, Cambridge, England
[7] Inst Metab Sci, Metab Res Labs, Cambridge, England
[8] Univ Cambridge, Dept Med, Cambridge, England
[9] Addenbrookes Hosp, Cambridge, England
[10] Addenbrookes Hosp, Dept Otolaryngol, Cambridge, England
基金
英国惠康基金; 英国工程与自然科学研究理事会;
关键词
Neurosurgery; Pituitary; Transsphenoidal; Outcome; Adenoma; Core outcome sets; INSTITUTE;
D O I
10.1007/s11102-023-01303-w
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
PurposeTranssphenoidal surgery is an established treatment for pituitary adenomas. We examined outcomes and time points following transsphenoidal surgery for pituitary adenoma to identify reporting heterogeneity within the literature.MethodsA systematic review of studies that reported outcomes for transsphenoidal surgery for pituitary adenoma 1990-2021 were examined. The protocol was registered a priori and adhered to the PRISMA statement. Studies in English with > 10 patients (prospective) or > 500 patients (retrospective) were included.Results178 studies comprising 427,659 patients were included. 91 studies reported 2 or more adenoma pathologies within the same study; 53 studies reported a single pathology. The most common adenomas reported were growth hormone-secreting (n = 106), non-functioning (n = 101), and ACTH-secreting (n = 95); 27 studies did not state a pathology. Surgical complications were the most reported outcome (n = 116, 65%). Other domains included endocrine (n = 104, 58%), extent of resection (n = 81, 46%), ophthalmic (n = 66, 37%), recurrence (n = 49, 28%), quality of life (n = 25, 19%); and nasal (n = 18, 10%). Defined follow up time points were most reported for endocrine (n = 56, 31%), extent of resection (n = 39, 22%), and recurrence (n = 28, 17%). There was heterogeneity in the follow up reported for all outcomes at different time points: discharge (n = 9), < 30 days (n = 23), < 6 months (n = 64), < 1 year (n = 23), and > 1 year (n = 69).ConclusionOutcomes and follow up reported for transsphenoidal surgical resection of pituitary adenoma are heterogenous over the last 30 years. This study highlights the necessity to develop a robust, consensus-based, minimum, core outcome set. The next step is to develop a Delphi survey of essential outcomes, followed by a consensus meeting of interdisciplinary experts. Patient representatives should also be included. An agreed core outcome set will enable homogeneous reporting and meaningful research synthesis, ultimately improving patient care.
引用
下载
收藏
页码:171 / 181
页数:11
相关论文
共 50 条
  • [21] Results of Endoscopic Endonasal Transsphenoidal Surgery for Pituitary Adenomas
    Tataranu, L.
    Ciubotaru, V
    Dediu, A.
    PAPERS PRESENTED AT THE EANS ANNUAL MEETING, 2012, : 61 - 64
  • [22] Management of Pituitary Adenomas: Mononostril Endoscopic Transsphenoidal Surgery
    Darwish, Houssein
    El-Hadi, Usamah
    Haddad, Georges
    Najjar, Marwan
    BASIC AND CLINICAL NEUROSCIENCE, 2018, 9 (02) : 121 - 128
  • [23] Delayed hyponatremia following transsphenoidal surgery for pituitary adenomas
    Rajaratnam, Simon
    Rajshekhar, Vedantam
    CLINICAL ENDOCRINOLOGY, 2018, 89 : 41 - 42
  • [24] Delayed Complications After Transsphenoidal Surgery for Pituitary Adenomas
    Alzhrani, Gmaan
    Sivakumar, Walavan
    Park, Min S.
    Taussky, Philipp
    Couldwell, William T.
    WORLD NEUROSURGERY, 2018, 109 : 233 - 241
  • [25] Transsphenoidal Surgery for Mixed Pituitary Gangliocytoma-Adenomas
    Shepard, Matthew J.
    Elzoghby, Mohamed A.
    Ghanim, Daffer
    Lopes, M. Beatriz S.
    Jane, John A., Jr.
    WORLD NEUROSURGERY, 2017, 108 : 310 - 316
  • [26] TRANSSPHENOIDAL SURGERY FOR PITUITARY-ADENOMAS IN CHILDREN - COMMENT
    TINDALL, GT
    NEUROSURGERY, 1994, 34 (02) : 212 - 212
  • [27] Contemporary transsphenoidal surgery for pituitary adenomas with emphasis on complications
    Teramoto, A
    BIOMEDICINE & PHARMACOTHERAPY, 2002, 56 : 154S - 157S
  • [28] Endoscopic endonasal transsphenoidal surgery for functional pituitary adenomas
    Hofstetter, Christoph P.
    Shin, Benjamin J.
    Mubita, Lynn
    Huang, Clark
    Anand, Vijay K.
    Boockvar, John A.
    Schwartz, Theodore H.
    NEUROSURGICAL FOCUS, 2011, 30 (04)
  • [29] Efficacy of transsphenoidal surgery for pituitary tumor: A protocol for systematic review
    Wang, Wei-Feng
    Yang, Lin-Hong
    Han, Lin
    Li, Ming-Jun
    Xiao, Jian-Qi
    MEDICINE, 2019, 98 (06)
  • [30] Managing complications of endoscopic transsphenoidal surgery in pituitary adenomas
    Abhinav, Kumar
    Tyler, Matthew
    Dale, Oliver T.
    Mohyeldin, Ahmed
    Fernandez-Miranda, Juan C.
    Katznelson, Laurence
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2020, 15 (05) : 311 - 319